Crizanlizumab

From WikiMD.org
Jump to navigation Jump to search

Crizanlizumab (pronunciation: kri-zan-li-zu-mab) is a monoclonal antibody medication used for the treatment of sickle cell disease. It is marketed under the brand name Adakveo by Novartis.

Etymology

The name "Crizanlizumab" is derived from the International Nonproprietary Names (INN), which follow specific guidelines for naming monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "zu" infix denotes its humanized nature. The rest of the name does not carry specific meaning.

Pharmacology

Crizanlizumab is a monoclonal antibody that works by blocking P-selectin, a substance in the blood vessels that causes them to become sticky and leads to the formation of blood clots. By blocking P-selectin, crizanlizumab helps to reduce the frequency of pain crises in people with sickle cell disease.

Usage

Crizanlizumab is used to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. VOCs are a common painful complication of sickle cell disease and are caused by the blockage of blood flow in the vessels.

Side Effects

Common side effects of crizanlizumab include nausea, joint pain, back pain, and fever. Serious side effects may include severe allergic reactions.

See Also

References

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski